Telaprevir Labeling Advantages Should Offset Higher Price In Hepatitis C Battle
Vertex Pharmaceuticals' Incivek (telaprevir) has cleared FDA with labeling advantages that should enable it to win a majority of patients in the battle against Merck's competing protease inhibitor for hepatitis C, Victrelis (boceprevir).
You may also be interested in...
J&J Not Seeking To Undercut Incivek, Victrelis On Olysio’s Pricing
While Olysio will be priced higher than Incivek for the course of therapy, J&J has a broader strategy for use of the second-generation protease inhibitor. Market analysts are skeptical about the drug’s prospects even though it has some clear edges over the first-generation protease inhibitors for hepatitis C.
PhRMA To Assist Pay-For-Locate Trial Enrollment Tool To Boost Study Diversity
PhRMA takes an active role in shaping a new National Clinical Trial Network that aims to speed up enrollment of diverse study populations as FDA increases its push for minorities in clinical research.
Jonca Bull Brings Clinical Experience To FDA Minority Health Office
Bull returns to the agency after stints at Novartis and Genentech to become director of the Office of Minority Health.